Recap - The congrats this week went to PropThink contributor Ivan Deryugin for his early December suggestion to buy BDSI ahead of a crucial phase 3 readout. The position … Continue Reading
Read NowInsights - Our entire editorial team was in San Francisco this week for the annual confluence of biotech conferences – JP Morgan Healthcare, Biotech Showcase, and OneMedForum … Continue Reading
Read NowInsights - Of course you did – everyone did. Small-cap drug developer Intercept Pharmaceuticals (ICPT) climbed 540% in two days. Not only that, but the stock gapped up by 200 points on day one, almost … Continue Reading
Read NowRecap - Mr. Deryugin started off the week updating the thesis on antibiotic developer Cubist Pharmaceuticals (CBST), which acquired Trius Therapeutics (TSRX) and Optimer Pharmaceuticals (OPTR) in 2013. Cubist missed … Continue Reading
Read NowRecap - Happy holidays from the PropThink editorial team! We hope you’re enjoying time with friends and family as we wrap up another busy holiday season and … Continue Reading
Read NowInsights - AcelRx (ACRX) announced on Monday a partnership with Grunenthal GmbH for the commercialization of Zalviso, the company’s patient-controlled analgesia product, in Europe and Australia. On Thursday, AcelRx entered into … Continue Reading
Read NowInsights - PropThink readers who followed us into Enanta Pharmaceuticals (ENTA) in July saw their money double through this week. AbbVie (ABBV), which uses an Enanta-developed hepatitis drug (the protease … Continue Reading
Read Now
